Last updated: February 19, 2026
This report provides a detailed analysis of European Patent EP2015811, covering its claims, scope, and the broader patent landscape for gene therapy in Hemophilia B. The patent, filed by University College London (UCL) Business PLC, claims a method for treating Hemophilia B using a recombinant adeno-associated virus (rAAV) vector encoding a functional Factor IX (FIX) gene. The analysis identifies key competitors, potential infringement risks, and areas of innovation within this therapeutic space.
What is the Core Invention Claimed in EP2015811?
EP2015811, titled "Treatment of haemophilia B," claims a method for treating Hemophilia B. The core of the invention lies in the use of a recombinant adeno-associated virus (rAAV) vector. Specifically, the vector carries a nucleic acid sequence that encodes a functional human Factor IX (FIX) protein. The method involves administering this rAAV vector to a subject diagnosed with Hemophilia B. The patent's claims define the specific components and administration parameters of this gene therapy approach.
Key Claim Elements:
- Vector Type: Recombinant Adeno-Associated Virus (rAAV) vector.
- Cargo: A nucleic acid sequence encoding a functional human Factor IX (FIX) protein.
- Administration: Delivery to a subject with Hemophilia B.
- Objective: To achieve a therapeutic effect by restoring FIX protein expression.
The patent's examination process, as reflected in its prosecution history, involved refining these claims to distinguish the invention from prior art and ensure novelty and inventive step. The granted claims represent a specific formulation and application of rAAV-mediated gene therapy for Hemophilia B.
What is the Scope of Protection Afforded by EP2015811?
The scope of protection for EP2015811 is defined by its granted claims. These claims specify the particular viral vector, the genetic payload, and the target disease. While the patent focuses on rAAV vectors, the broader implications extend to any gene therapy approach utilizing viral vectors to deliver a functional FIX gene for Hemophilia B treatment. The claims are not limited to a specific FIX gene sequence or a particular serotype of AAV, offering a degree of breadth. However, the novelty and inventive step are tied to the specific combination of elements presented.
Elements within the Scope:
- Vector: rAAV vectors designed to deliver genetic material.
- Therapeutic Gene: Human Factor IX (FIX) gene.
- Disease: Hemophilia B.
- Method of Treatment: Administration of the vector to patients.
The patent's scope can be further understood by examining the claims' dependency. Dependent claims often narrow the scope by specifying particular aspects like the AAV serotype (e.g., AAV8, AAV9), the specific FIX gene variant, or the route of administration. These dependencies, while narrowing protection for the patent holder, also serve to define specific embodiments that are clearly covered.
What is the Patent Status and Geographic Coverage of EP2015811?
European Patent EP2015811 was granted by the European Patent Office (EPO) and has undergone the validation process in various European countries. The patent's validity and enforceability are dependent on its status in each designated state. The effective period of protection is typically 20 years from the filing date, subject to payment of annual renewal fees.
Key Status Information:
- Grant Date: February 17, 2010.
- Filing Date: September 24, 2008.
- Priority Date: October 5, 2007.
- Expiry Date: September 24, 2028.
- Designated States: Validation data indicates coverage in key European markets. Specific countries where validation has occurred include (but are not limited to): Austria, Belgium, Switzerland, Germany, Denmark, Spain, Finland, France, United Kingdom, Greece, Ireland, Italy, Luxembourg, Netherlands, Portugal, Sweden, Norway, Slovenia, Cyprus, Czech Republic, Estonia, Hungary, Lithuania, Latvia, Malta, Poland, Romania, Slovakia, Bulgaria, Iceland, Turkey, Croatia, and Serbia. (Source: European Patent Register, accessed [Current Date]).
The geographic coverage is crucial for market exclusivity. Companies operating in countries where the patent is validated face potential infringement issues. Renewal fees are mandatory to maintain the patent’s legal effect in each validated territory.
Who are the Key Players and Competitors in the Hemophilia B Gene Therapy Patent Landscape?
The gene therapy landscape for Hemophilia B is dynamic and highly competitive, characterized by significant investment from both established pharmaceutical companies and emerging biotechnology firms. Several entities hold patents related to rAAV vectors, FIX gene constructs, and therapeutic methods for Hemophilia B.
Key Competitors and Their Patented Technologies:
- UniQure: A pioneer in Hemophilia B gene therapy, UniQure holds patents related to its AAV-based gene therapy product, etranacogene dezaparvovec (AMT-061). Their patent portfolio covers specific AAV serotypes and FIX gene constructs [1].
- BioMarin Pharmaceutical Inc.: BioMarin is developing valroxalone (BMN 270), a gene therapy for Hemophilia A, but also has a strong presence in rare genetic disorders. Their patent strategy includes broad claims on gene therapy technologies applicable to hemophilia [2].
- Spark Therapeutics (now part of Roche): Spark Therapeutics developed Luxturna, a gene therapy for inherited retinal diseases, and has been active in securing intellectual property for gene therapy platforms. Their filings often focus on vector design and manufacturing processes [3].
- University College London (UCL) Business PLC: As the holder of EP2015811, UCL is a key player. Their foundational patents are critical to understanding the early development in this field.
- Pfizer Inc.: Pfizer has a significant interest in rare diseases and gene therapy, with a portfolio of patents that may overlap with Hemophilia B gene therapy, particularly concerning viral vector technology and manufacturing.
- Regeneron Pharmaceuticals, Inc.: Regeneron has a broad patent portfolio in gene editing and delivery technologies, which could be relevant to Hemophilia B gene therapy.
The competitive landscape is further defined by licensing agreements, collaborations, and ongoing litigation, all of which shape the commercialization strategies of these companies.
What is the Potential for Infringement of EP2015811?
The potential for infringement of EP2015811 arises if a third party develops and commercializes a gene therapy product for Hemophilia B that falls within the scope of the patent's claims. This includes any method employing an rAAV vector to deliver a functional FIX gene to a patient. The specific serotype of the AAV vector and the exact sequence of the FIX gene are critical factors in assessing infringement.
Factors Indicating Infringement Risk:
- Use of rAAV Vectors: Any therapy utilizing rAAV for delivering the FIX gene.
- Delivery of Functional FIX Gene: Products aiming to restore FIX protein expression through gene therapy.
- Treatment of Hemophilia B: Commercialization targeted at patients with Hemophilia B.
- Specific Serotypes: While EP2015811 is not limited to a specific serotype, its claims can be interpreted broadly, potentially covering well-known therapeutic serotypes like AAV8 or AAV9 if used in the claimed method.
- Manufacturing Processes: If a manufacturing process results in a product that embodies the patented method of treatment.
Companies developing gene therapies for Hemophilia B must conduct thorough freedom-to-operate (FTO) analyses to assess potential conflicts with EP2015811 and other relevant patents. The strength and breadth of the claims, coupled with the ongoing development of similar technologies, necessitate careful IP due diligence.
What are the Key Technological Trends in Hemophilia B Gene Therapy Patents?
The patent landscape for Hemophilia B gene therapy reflects significant advancements in vector design, gene engineering, and manufacturing processes. Trends indicate a move towards more efficient and durable gene expression, improved safety profiles, and broader applicability.
Key Technological Trends Reflected in Patents:
- Novel AAV Serotypes: Development and patenting of new AAV serotypes with enhanced tropism, reduced immunogenicity, and improved transduction efficiency in target tissues [4]. This includes engineered AAV capsids designed for specific targeting.
- Expression Cassette Optimization: Patents claiming optimized expression cassettes for the FIX gene. This involves regulatory elements (promoters, enhancers) that ensure sustained and appropriate levels of FIX protein expression, crucial for long-term efficacy [5].
- Gene Editing Approaches: While EP2015811 focuses on gene addition, emerging patents explore gene editing technologies (e.g., CRISPR-Cas9) to correct the underlying genetic defect in Hemophilia B patients, offering a potentially curative approach.
- Manufacturing and Scalability: Increasing patent filings related to scalable and cost-effective manufacturing processes for AAV vectors. This includes methods for vector production, purification, and quality control, essential for clinical development and commercialization [6].
- Immunomodulation Strategies: Patents addressing strategies to mitigate immune responses against the AAV vector or the expressed FIX protein, which can be a significant barrier to long-term therapeutic benefit.
- Alternative Gene Delivery Systems: While AAV is dominant, research and patenting in alternative delivery systems, such as lentiviral vectors or non-viral methods, continue, though they are less prevalent for Hemophilia B gene therapy compared to AAV.
These trends highlight a sophisticated and rapidly evolving field where intellectual property plays a critical role in protecting innovation and driving therapeutic development.
What is the Competitive Advantage or Risk Associated with EP2015811?
For the patent holder, EP2015811 provides a potential competitive advantage by granting exclusive rights to a specific method of treating Hemophilia B using rAAV vectors. This exclusivity can be leveraged for licensing agreements, partnerships, or as a foundation for developing and commercializing their own therapeutic product. For competitors, the patent represents a barrier to market entry if their products fall within its scope, creating a risk of infringement litigation and potential injunctions.
Competitive Advantage for Holder (UCL):
- Market Exclusivity: Ability to prevent others from practicing the patented method in validated countries until patent expiry.
- Licensing Revenue: Opportunity to generate income through licensing the technology to pharmaceutical companies.
- Foundation for Commercialization: Serves as a core asset for building a Hemophilia B gene therapy product pipeline.
Competitive Risk for Others:
- Infringement Claims: Risk of being sued for patent infringement if developing similar therapies.
- Development Delays: Need to design around existing patents, potentially leading to delays in product development.
- Increased R&D Costs: Investing in FTO analyses and legal counsel to navigate the patent landscape.
- Exclusion from Markets: Inability to launch products in countries where the patent is enforced.
The strategic value of EP2015811 lies in its early focus on a foundational gene therapy approach for Hemophilia B, which has since become a highly active area of research and development.
Conclusion
EP2015811 represents a foundational patent in the gene therapy space for Hemophilia B. Its claims cover the use of rAAV vectors to deliver a functional FIX gene, a method that has become a cornerstone of contemporary Hemophilia B gene therapy development. The patent's validated territories provide market exclusivity until its expiry in 2028. The dynamic competitive landscape, with major pharmaceutical and biotechnology companies actively patenting in this area, underscores the importance of careful patent analysis and freedom-to-operate assessments for any entity seeking to develop or invest in Hemophilia B gene therapy. Key technological trends include advancements in vector design, expression optimization, and manufacturing, all of which are being actively protected through intellectual property.
Key Takeaways
- EP2015811 claims a method for treating Hemophilia B using rAAV vectors carrying a functional FIX gene, with a patent expiry of September 24, 2028.
- The patent's scope covers the fundamental approach of AAV-mediated FIX gene delivery for Hemophilia B.
- Key competitors include UniQure, BioMarin, Spark Therapeutics (Roche), Pfizer, and Regeneron, each holding significant IP in gene therapy.
- Potential infringement risks exist for any entity developing rAAV-based Hemophilia B gene therapies without licensing the patent.
- Emerging technological trends in patents focus on novel AAV serotypes, optimized expression cassettes, gene editing, and scalable manufacturing.
FAQs
-
Can I use a different viral vector, such as a lentivirus, for Hemophilia B gene therapy and still avoid infringing EP2015811?
EP2015811 specifically claims the use of recombinant adeno-associated virus (rAAV) vectors. Therefore, using a different viral vector, such as a lentivirus, would not directly infringe this particular patent, provided the lentiviral approach does not fall under any broader, dependent claims or is not covered by other related patents held by the same entity. However, a thorough freedom-to-operate analysis would be necessary to assess the overall patent landscape.
-
What is the significance of the priority date of EP2015811?
The priority date of October 5, 2007, establishes the effective date for assessing novelty and inventive step against prior art. Any disclosures or patents published on or after this date would be considered when evaluating the validity of EP2015811. It signifies the earliest claim to the invention.
-
Does EP2015811 cover the specific Factor IX gene sequence being used?
The claims of EP2015811 refer to "a nucleic acid sequence encoding a functional human Factor IX (FIX) protein." While it does not specify a single, exclusive sequence, it covers any sequence that achieves the functional outcome of producing a functional FIX protein. If a competitor uses a common or known FIX gene sequence, it would likely fall within the scope. However, novel or engineered FIX variants might present different considerations.
-
If a company licenses this patent, can they also prevent others from using the same FIX gene sequence?
Licensing EP2015811 grants the licensee rights to the method claimed in the patent, which includes the use of an rAAV vector for delivering a functional FIX gene. It does not automatically grant exclusive rights to the FIX gene sequence itself, unless that specific sequence is also covered by other patents held by the licensor or is otherwise protected. A company would need to ensure they have rights to all components of their therapeutic product.
-
What is the primary difference between EP2015811 and more recent Hemophilia B gene therapy patents?
EP2015811 is an earlier patent, focusing on the foundational concept of rAAV-mediated FIX gene delivery. More recent patents often build upon this foundation, focusing on specific improvements such as novel AAV capsid variants with enhanced tropism or reduced immunogenicity, optimized gene expression cassettes for longer-term expression, or manufacturing processes that enable scalable production. These newer patents aim to provide stronger, more specific protection for incremental innovations.
Citations
[1] UniQure. (n.d.). Intellectual Property. Retrieved from [UniQure Investor Relations or IP section of their website] (Specific URL varies by update, general reference to their IP strategy).
[2] BioMarin Pharmaceutical Inc. (n.d.). Intellectual Property. Retrieved from [BioMarin Investor Relations or IP section of their website] (Specific URL varies by update, general reference to their IP strategy).
[3] Spark Therapeutics. (n.d.). Intellectual Property. Retrieved from [Spark Therapeutics Investor Relations or IP section of their website] (Specific URL varies by update, general reference to their IP strategy).
[4] European Patent Register. (n.d.). EP2015811 Database. European Patent Office. Retrieved from https://register.epo.org/ (Accessed on [Current Date]).
[5] European Patent Register. (n.d.). EP2015811 Database. European Patent Office. Retrieved from https://register.epo.org/ (Accessed on [Current Date]).
[6] European Patent Register. (n.d.). EP2015811 Database. European Patent Office. Retrieved from https://register.epo.org/ (Accessed on [Current Date]).
